National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Calcifediol monohydrate (Dnord®). HTA ID: 22063

Calcifediol monohydrate is indicated for the treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/09/2022
Rapid review completed 13/10/2022
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that calcifediol monohydrate (Dnord®) be considered for reimbursement.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.